Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention
Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface an...
Saved in:
| Published in: | World journal of gastroenterology : WJG Vol. 25; no. 26; p. 3299 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
14.07.2019
|
| Subjects: | |
| ISSN: | 2219-2840, 2219-2840 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface antigen (HBsAg)-negative/anti-HBc-positive subjects may revert to HBsAg-positive. In patients with hemo-lymphoproliferative disease, the frequency of HBV reactivation depends on the type of lymphoproliferative disorder, the individual's HBV serological status and the potency and duration of immunosuppression. In particular, it occurs in 10%-50% of the HBsAg-positive and in 2%-25% of the HBsAg- negative/anti-HBc-positive, the highest incidences being registered in patients receiving rituximab-based therapy. HBV reactivation can be prevented by accurate screening of patients at risk and by a pharmacological prophylaxis with anti-HBV nucleo(t)sides starting 2-3 wk before the beginning of immunosuppressive treatment and covering the entire period of administration of immunosuppressive drugs and a long subsequent period, the duration of which depends substantially on the degree of immunodepression achieved. Patients with significant HBV replication before immunosuppressive therapy should receive anti-HBV nucleo(t)sides as a long-term (may be life-long) treatment. This review article is mainly directed to doctors engaged every day in the treatment of patients with onco-lymphoproliferative diseases, so that they can broaden their knowledge on HBV infection and on its reactivation induced by the drugs with high immunosuppressive potential that they use in the care of their patients. |
|---|---|
| AbstractList | Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface antigen (HBsAg)-negative/anti-HBc-positive subjects may revert to HBsAg-positive. In patients with hemo-lymphoproliferative disease, the frequency of HBV reactivation depends on the type of lymphoproliferative disorder, the individual's HBV serological status and the potency and duration of immunosuppression. In particular, it occurs in 10%-50% of the HBsAg-positive and in 2%-25% of the HBsAg- negative/anti-HBc-positive, the highest incidences being registered in patients receiving rituximab-based therapy. HBV reactivation can be prevented by accurate screening of patients at risk and by a pharmacological prophylaxis with anti-HBV nucleo(t)sides starting 2-3 wk before the beginning of immunosuppressive treatment and covering the entire period of administration of immunosuppressive drugs and a long subsequent period, the duration of which depends substantially on the degree of immunodepression achieved. Patients with significant HBV replication before immunosuppressive therapy should receive anti-HBV nucleo(t)sides as a long-term (may be life-long) treatment. This review article is mainly directed to doctors engaged every day in the treatment of patients with onco-lymphoproliferative diseases, so that they can broaden their knowledge on HBV infection and on its reactivation induced by the drugs with high immunosuppressive potential that they use in the care of their patients.Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface antigen (HBsAg)-negative/anti-HBc-positive subjects may revert to HBsAg-positive. In patients with hemo-lymphoproliferative disease, the frequency of HBV reactivation depends on the type of lymphoproliferative disorder, the individual's HBV serological status and the potency and duration of immunosuppression. In particular, it occurs in 10%-50% of the HBsAg-positive and in 2%-25% of the HBsAg- negative/anti-HBc-positive, the highest incidences being registered in patients receiving rituximab-based therapy. HBV reactivation can be prevented by accurate screening of patients at risk and by a pharmacological prophylaxis with anti-HBV nucleo(t)sides starting 2-3 wk before the beginning of immunosuppressive treatment and covering the entire period of administration of immunosuppressive drugs and a long subsequent period, the duration of which depends substantially on the degree of immunodepression achieved. Patients with significant HBV replication before immunosuppressive therapy should receive anti-HBV nucleo(t)sides as a long-term (may be life-long) treatment. This review article is mainly directed to doctors engaged every day in the treatment of patients with onco-lymphoproliferative diseases, so that they can broaden their knowledge on HBV infection and on its reactivation induced by the drugs with high immunosuppressive potential that they use in the care of their patients. Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface antigen (HBsAg)-negative/anti-HBc-positive subjects may revert to HBsAg-positive. In patients with hemo-lymphoproliferative disease, the frequency of HBV reactivation depends on the type of lymphoproliferative disorder, the individual's HBV serological status and the potency and duration of immunosuppression. In particular, it occurs in 10%-50% of the HBsAg-positive and in 2%-25% of the HBsAg- negative/anti-HBc-positive, the highest incidences being registered in patients receiving rituximab-based therapy. HBV reactivation can be prevented by accurate screening of patients at risk and by a pharmacological prophylaxis with anti-HBV nucleo(t)sides starting 2-3 wk before the beginning of immunosuppressive treatment and covering the entire period of administration of immunosuppressive drugs and a long subsequent period, the duration of which depends substantially on the degree of immunodepression achieved. Patients with significant HBV replication before immunosuppressive therapy should receive anti-HBV nucleo(t)sides as a long-term (may be life-long) treatment. This review article is mainly directed to doctors engaged every day in the treatment of patients with onco-lymphoproliferative diseases, so that they can broaden their knowledge on HBV infection and on its reactivation induced by the drugs with high immunosuppressive potential that they use in the care of their patients. |
| Author | Sagnelli, Caterina Sagnelli, Evangelista Coppola, Nicola Martini, Salvatore Pisaturo, Mariantonietta Calò, Federica |
| Author_xml | – sequence: 1 givenname: Caterina surname: Sagnelli fullname: Sagnelli, Caterina email: sagnelli.caterina@libero.it organization: Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples 80127, Italy. sagnelli.caterina@libero.it – sequence: 2 givenname: Mariantonietta surname: Pisaturo fullname: Pisaturo, Mariantonietta organization: Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples 80127, Italy – sequence: 3 givenname: Federica surname: Calò fullname: Calò, Federica organization: Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples 80127, Italy – sequence: 4 givenname: Salvatore surname: Martini fullname: Martini, Salvatore organization: Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples 80127, Italy – sequence: 5 givenname: Evangelista surname: Sagnelli fullname: Sagnelli, Evangelista organization: Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples 80127, Italy – sequence: 6 givenname: Nicola surname: Coppola fullname: Coppola, Nicola organization: Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples 80127, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31341357$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LxDAQhoOsuO7q3ZPk6MHWZJK06VEXv2BBED2XtJ24Wfpl03bZf2_VFTzNC88zL8MsyKxuaiTkgrNQxFLf7LYf4QgqdBCFApLkiJwC8CQALdnsX56ThfdbxkAIBSdkLriQXKj4lHSvaPLejaZ3TU0bSzfYTrl3nt7R0XWDp662mP9gV9NviHXv6c71m0mumqDcV-2mabumdBa7iY9IC-fRePTX1NQFdZPfdjhOi1PNGTm2pvR4fphL8v5w_7Z6CtYvj8-r23WQiyTqgwxFnlnDtLLILSAXhiVcMRFrFWljpMqZ1DJKsojbyHBQqsi01TpmmEAWw5Jc_fZOp30O6Pu0cj7HsjQ1NoNPASIJIDmXk3p5UIeswiJtO1eZbp_-_Qm-AFCKbrc |
| CitedBy_id | crossref_primary_10_1007_s10147_020_01814_7 crossref_primary_10_1097_INF_0000000000003730 crossref_primary_10_1097_MD_0000000000031962 crossref_primary_10_12998_wjcc_v9_i21_5769 crossref_primary_10_3390_biomedicines10020443 crossref_primary_10_2478_rrlm_2020_0039 crossref_primary_10_1186_s40425_019_0790_y crossref_primary_10_3390_pathogens11050567 crossref_primary_10_3390_jpm11040267 crossref_primary_10_1007_s15004_021_8573_2 crossref_primary_10_3390_jcm10215201 crossref_primary_10_1111_bjh_17143 crossref_primary_10_1515_med_2020_0130 crossref_primary_10_1007_s11654_020_00221_8 crossref_primary_10_1515_med_2019_0088 crossref_primary_10_3390_livers3030026 crossref_primary_10_1111_apt_70228 crossref_primary_10_1111_jvh_13248 crossref_primary_10_1515_med_2020_0005 crossref_primary_10_1515_med_2020_0018 crossref_primary_10_3389_fimmu_2021_751754 crossref_primary_10_3390_pathogens11070816 crossref_primary_10_3390_cancers11111819 crossref_primary_10_3389_fonc_2021_685706 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3748/wjg.v25.i26.3299 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 2219-2840 |
| ExternalDocumentID | 31341357 |
| Genre | Journal Article Review |
| GroupedDBID | --- 123 29R 2WC 36B 53G 5VR 8WL AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CGR CHBEP CIEJG CS3 CUY CVF CW9 DIK DU5 E3Z EBS ECM EIF EJD F5P FA0 FRP GX1 HYE M~E NPM OK1 P2P RNS RPM TR2 XSB 7X8 |
| ID | FETCH-LOGICAL-c396t-be3cbfa085fe1f2e13a09150378568aa45c048469b61f6a1255db8f8870e92b72 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 27 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000475373600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2219-2840 |
| IngestDate | Fri Jul 11 16:12:38 EDT 2025 Thu Jan 02 23:00:37 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 26 |
| Keywords | Hepatitis B virus reactivation Hemo-lymphoproliferative diseases Immunosuppressive therapy Hepatitis B virus prophylasis Hepatitis B virus therapy Hepatitis B virus infection |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c396t-be3cbfa085fe1f2e13a09150378568aa45c048469b61f6a1255db8f8870e92b72 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.wjgnet.com/1007-9327/full/v25/i26/3299.htm |
| PMID | 31341357 |
| PQID | 2264224114 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2264224114 pubmed_primary_31341357 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-Jul-14 20190714 |
| PublicationDateYYYYMMDD | 2019-07-14 |
| PublicationDate_xml | – month: 07 year: 2019 text: 2019-Jul-14 day: 14 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | World journal of gastroenterology : WJG |
| PublicationTitleAlternate | World J Gastroenterol |
| PublicationYear | 2019 |
| SSID | ssj0023352 |
| Score | 2.4095347 |
| SecondaryResourceType | review_article |
| Snippet | Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3299 |
| SubjectTerms | Antibiotic Prophylaxis - methods Antiviral Agents - therapeutic use DNA, Viral - blood Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B - virology Hepatitis B Antibodies - blood Hepatitis B Antibodies - immunology Hepatitis B Surface Antigens - blood Hepatitis B Surface Antigens - immunology Hepatitis B virus - genetics Hepatitis B virus - immunology Hepatitis B virus - isolation & purification Humans Immunosuppressive Agents - adverse effects Lymphoproliferative Disorders - drug therapy Lymphoproliferative Disorders - immunology Time Factors Virus Activation - drug effects Virus Activation - immunology |
| Title | Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31341357 https://www.proquest.com/docview/2264224114 |
| Volume | 25 |
| WOSCitedRecordID | wos000475373600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LS8MwGA_qPHjxga_5IoJHszVNk7QnUXF4cQxR2K00aaIVbeu6Tfzv_dJ2ehPBS-khhfLle_y-N0JnmgobBUoTzqKQBAABCKDwiAiArtILteRS1csm5HAYjsfRqA24VW1Z5UIn1oo6LbSLkfddw6czNzS4KN-J2xrlsqvtCo1l1GEAZVxJlxx_ZxF810_klsuBVBJQw16TpnQDV_ofL0-9uc97mS96zI9-AZi1oRls_PcXN9F6CzHxZcMTW2jJ5Ntocm9cC0MTgMWFxc_G1VJPswpf4Xk2mVV4UZeVwxtu561W2AVq4fBbQV4_4eaL0q35saYZGI7b_E51jpM8xRmcL9uZUEW-gx4HNw_Xt6Tdt0A0i8SUKMO0sgmAMGuo9Q1lCaAJ7jEZchEmScA1yDv400pQKxKARjxVoQU15ZnIV9LfRSt5kZt9hEXKAgBq1FLwV2jKFXhOAuyxNuCReZHtotMFCWPgZ5ekSHJTzKr4h4hdtNfcQ1w2gzdi5qbPMS4P_vD1IVoDbOMatAgNjlDHgjSbY7Sq50DZyUnNKPAcju6-ALNryS8 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reactivation+of+hepatitis+B+virus+infection+in+patients+with+hemo-lymphoproliferative+diseases%2C+and+its+prevention&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Sagnelli%2C+Caterina&rft.au=Pisaturo%2C+Mariantonietta&rft.au=Cal%C3%B2%2C+Federica&rft.au=Martini%2C+Salvatore&rft.date=2019-07-14&rft.issn=2219-2840&rft.eissn=2219-2840&rft.volume=25&rft.issue=26&rft.spage=3299&rft_id=info:doi/10.3748%2Fwjg.v25.i26.3299&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2219-2840&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2219-2840&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2219-2840&client=summon |